Advanced

EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with (90)Y-radiolabelled ibritumomab tiuxetan (Zevalin).

Tennvall, Jan LU ; Fischer, Manfred; Bischof Delaloye, Angelika; Bombardieri, Emilio; Bodei, Lisa; Giammarile, Francesco; Lassmann, Michael; Oyen, Wim and Brans, Boudewijn (2007) In European Journal of Nuclear Medicine and Molecular Imaging 34(4). p.616-622
Abstract
Background In January 2004, EMEA approved Y-90-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine. Purpose The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radio-immunotherapy. The guideline... (More)
Background In January 2004, EMEA approved Y-90-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine. Purpose The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radio-immunotherapy. The guideline also stresses the need for close collaboration with the physician(s) treating the patient for the underlying disease. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
guidelines, nuclear medicine, Y-90-ibritumomab tiuxetan, non-Hodgkin's, lymphoma, radioimmunotherapy
in
European Journal of Nuclear Medicine and Molecular Imaging
volume
34
issue
4
pages
616 - 622
publisher
Springer
external identifiers
  • wos:000244951300031
  • scopus:33947273534
ISSN
1619-7070
DOI
10.1007/s00259-007-0372-y
language
English
LU publication?
yes
id
1d94035a-23aa-40c5-ad2d-936600ada96f (old id 165422)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17323056&dopt=Abstract
date added to LUP
2007-07-24 11:11:25
date last changed
2017-06-04 03:32:38
@article{1d94035a-23aa-40c5-ad2d-936600ada96f,
  abstract     = {Background In January 2004, EMEA approved Y-90-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine. Purpose The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radio-immunotherapy. The guideline also stresses the need for close collaboration with the physician(s) treating the patient for the underlying disease.},
  author       = {Tennvall, Jan and Fischer, Manfred and Bischof Delaloye, Angelika and Bombardieri, Emilio and Bodei, Lisa and Giammarile, Francesco and Lassmann, Michael and Oyen, Wim and Brans, Boudewijn},
  issn         = {1619-7070},
  keyword      = {guidelines,nuclear medicine,Y-90-ibritumomab tiuxetan,non-Hodgkin's,lymphoma,radioimmunotherapy},
  language     = {eng},
  number       = {4},
  pages        = {616--622},
  publisher    = {Springer},
  series       = {European Journal of Nuclear Medicine and Molecular Imaging},
  title        = {EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with (90)Y-radiolabelled ibritumomab tiuxetan (Zevalin).},
  url          = {http://dx.doi.org/10.1007/s00259-007-0372-y},
  volume       = {34},
  year         = {2007},
}